CSPAN3 Food Drug Administration Oversight January 17, 2018
Play. I want to thank allen and pew for hosting this meeting, for organizing the publishing of the special supplement and of course to mr. Gottlieb for his remarks at the beginning of the day. So the focus of this final panel today is the fact that in certain high profile cases manufacturers have released incorrect or incomplete information into the market that was directly counter to the information, the contemporaneous information the fda had. They noted that selective publication of Clinical Trial results has in the past created a misleading picture of the safety and efficacy of a product w...